Novartis AG

The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety (2021) Kunz P, Caplin ME, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials (2021) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, et al. Journal article Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies (2021) Schett G, Baraliakos X, Van Den Bosch F, Deodhar A, Ostergaard M, Das Gupta A, Mpofu S, et al. Journal article Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article Trotz einer großen Auswahl wirksame Medikamente: Psoriatiker scheinen immer noch untertherapiert zu sein (2021) Pilz AC, Zink A, Schielein MC, Hell K, Romer K, Hillmann E, Bäumer D, et al. Journal article LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)-30-MONTH DATA FROM THE RELIANCE REGISTRY (2021) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen P, Janda A, Rech J, Kallinich T, Weller-Heinemann F, et al. Conference contribution RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL (2021) Boers M, Conaghan PG, Schett G, Mandl P, Naredo E, Van Den Bosch F, Burgos-Vargas R, et al. Conference contribution TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY (2021) D'Agostino MA, Conaghan PG, Gaillez C, Boers M, Naredo E, Carron P, Hanova P, et al. Conference contribution ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB OR ADALIMUMAB: A POST HOC ANALYSIS OF EXCEED (2021) Kaeley GS, Schett G, Conaghan PG, Mcgonagle D, Behrens F, Goupille P, Gaillez C, et al. Conference contribution EFFICACY AND SAFETY OF SECUKINUMAB IN PATIENTS WITH ROTATOR CUFF TENDINOPATHY: A 24-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II PROOF-OF-CONCEPT TRIAL (2021) Millar NL, Mcinnes I, Mindeholm L, Seroutou A, Praestgaard J, Schramm U, Levitch R, et al. Conference contribution